36
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Efficient Purification of GP-1D8 Glycoprotein from Human Breast Carcinoma Tissue by Immunoaffinity Chromatography

, &
Pages 321-333 | Received 12 Apr 2008, Accepted 10 May 2008, Published online: 17 Sep 2008
 

Abstract

Anti-GP-1D8 monoclonal antibody was produced in our laboratory. Immunoaffinity purification of GP-1D8 glycoprotein from human breast carcinoma tissues, on column with the monospecific antibody, is developed. The procedure permits purification of GP-1D8 to a highly purified state. It appeared as a single band in sodium dodcyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The molecular mass of GP-1D8 was determined to be 66 kDa by mass spectrometry. Its antigenicity was stable between 0 and 70°C. It was breast cancer specific, as determined by immunohistochemistry and immunocytochemistry. The preparation of anti-GP-1D8 monoclonal antibody will facilitate further detection of, and functional study on, GP-1D8. The study also provides a simple, economical, and efficient method for affinity purification of target proteins from human or animal tissues.

ACKNOWLEDGMENT

We thank Professor Yuxian Zhu (College of Life Sciences, Peking University) for constructive discussions and giving us some help for accomplishing this work. This work was supported by National Natural Science Foundation of China (No. 30571711) to Renqing Feng.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.